Dermatology Doctors in Maple Grove, MN Accepting Medicare

6 Dermatology doctors found. Showing 1 - 6

Jeannie Therese Larson, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 9555 Upland Lane N, Maple Grove, MN 55369 Phone: 952-993-3260

Ronda Farah, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 14500 99th Ave N, Maple Grove, MN 55369 Phone: 763-898-1570    Fax: 763-898-1576

Dr. Kathleen Maccarthy Demanivel, MD Dermatology Medicare: Medicare Enrolled Practice Location: 14500 99th Ave N, Maple Grove, MN 55369 Phone: 763-898-1000

Dr. Sheilagh M Maguiness, MD Dermatology - Pediatric Dermatology Medicare: Accepting Medicare Assignments Practice Location: 14500 99th Ave N, Maple Grove, MN 55369 Phone: 763-898-1000

Amrita Goyal-o'leary, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 9555 Upland Ln N, Maple Grove, MN 55369 Phone: 952-993-3376

Heidi G H Cole, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 9555 Upland Lane North, Maple Grove, MN 55369 Phone: 952-993-1440

News Archive

Epigenetic link found between prenatal exposure to maternal smoking and offspring's cardio-metabolic health

According to new research, epigenetic changes found in the offspring exposed to maternal smoking during pregnancy or in current smokers are linked to smoking-related diseases in adulthood.

Majority of people were unprepared and did not have a pandemic plan, survey reveals

Researchers point out that if these healthy individuals had a challenging time absorbing COVID-related information, then such challenges may be even greater in people with limited educational opportunities or with neurocognitive disorders, such as Alzheimer's disease or a brain injury, due to low health literacy and impaired memory.

NHS should remove unproven apps from library, say experts

There is no proof that 85% of the depression apps currently recommended by the NHS for patients to manage their condition actually work, say experts in the journal Evidence Based Mental Health.

Intercept signs CRADA with NIDDK for study of obeticholic acid in nonalcoholic steatohepatitis

Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic diseases, today announced the signing of a cooperative research and development agreement (CRADA) with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health to conduct a double blind, multi-center, study to evaluate the effects of obeticholic acid in patients with nonalcoholic steatohepatitis (NASH).

Read more Medical News

› Verified 8 days ago